Stock BLRX BIOLINERX LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Financials BioLineRx Ltd.

Equities

BLRX

IL0011015182

Biotechnology & Medical Research

Delayed TEL AVIV STOCK EXCHANGE
Other stock markets
 15:24:26 08/05/2024 BST 		5-day change 1st Jan Change
16.5 ILa -1.20% Intraday chart for BioLineRx Ltd. -7.82% -56.81%
04-17 BioLineRx Ltd. Announces Poster Presentation on Apheresis Center Efficiency and CXCR4 Antagonists Including APHEXDA® (Motixafortide) in Patients with Multiple Myeloma at the ASFA 2024 Annual Meeting CI
04-10 BioLineRx Ltd. Accesses Second Tranche of $20 Million Under Previously Announced $40 Million Non-Dilutive Debt Financing Agreement CI

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025
Capitalization 1 26.71 59.87 99.49 28.52 114.9 53.23 -
Enterprise Value (EV) 1 26.71 59.87 99.49 28.52 114.9 53.23 53.23
P/E ratio - - - -1.33 x -1.76 x -2.22 x -
Yield - - - - - - -
Capitalization / Revenue - - - - 23.9 x 3.71 x 1.92 x
EV / Revenue - - - - 23.9 x 3.71 x 1.92 x
EV / EBITDA -0.98 x -2.72 x -4.13 x -1 x -2.35 x -0.89 x -0.91 x
EV / FCF - - - - - - -
FCF Yield - - - - - - -
Price to Book - - - - - - -
Nbr of stocks (in thousands) 171,270 349,170 715,156 715,156 1,086,589 1,199,089 -
Reference price 2 0.1559 0.1715 0.1391 0.0399 0.1058 0.0444 0.0444
Announcement Date 12/03/20 23/02/21 16/03/22 22/03/23 26/03/24 - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025
Net sales 1 - - - - 4.8 14.36 27.77
EBITDA 1 -27.17 -21.99 -24.07 -28.5 -48.99 -59.8 -58.8
EBIT 1 -28.11 -22.93 -24.78 -29.16 -49.69 -39.24 -30.4
Operating Margin - - - - -1,035.29% -273.16% -109.46%
Earnings before Tax (EBT) 1 -25.45 -30.02 -27.05 -24.95 -60.61 -47.78 -37.65
Net income 1 -25.45 -30.02 -27.05 -24.95 -60.61 -47.28 -36.65
Net margin - - - - -1,262.79% -329.12% -131.96%
EPS 2 - - - -0.0300 -0.0600 -0.0200 -
Free Cash Flow - - - - - - -
FCF margin - - - - - - -
FCF Conversion (EBITDA) - - - - - - -
FCF Conversion (Net income) - - - - - - -
Dividend per Share - - - - - - -
Announcement Date 12/03/20 23/02/21 16/03/22 22/03/23 26/03/24 - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2020 S1 2021 S1 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 S1 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 S1 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 S1 2024 Q3 2024 Q4
Net sales 1 - - - - - - - - - - - - - 4.8 0.34 0.47 0.81 4.69 6.91
EBITDA 1 -11.97 -11.6 -6.05 -6.424 -5.906 -7.461 -13.37 -6.925 -8.211 -8.597 -9.717 -18.31 -12.14 -18.54 -16.8 -17.1 -33.9 -13.7 -12.2
EBIT - - -6.217 -6.598 -6.079 -7.602 - -7.078 -8.398 -8.856 -9.915 -18.77 -12.36 -18.57 - - - - -
Operating Margin - - - - - - - - - - - - - -386.79% - - - - -
Earnings before Tax (EBT) 1 -13.42 -17.03 -5.716 -4.304 -4.93 -7.443 -12.37 -6.847 -5.731 -12.16 -18.54 -30.71 -16.2 -13.88 -21 -21.3 -42.3 -17.9 -16.5
Net income 1 -13.42 -17.03 -5.716 -4.304 -4.93 -7.443 -12.37 -6.847 -5.731 -12.16 -18.54 -30.71 -16.2 -13.88 -21 -21.3 -42.3 -17.9 -16.5
Net margin - - - - - - - - - - - - - -289.25% -6,176.47% -4,531.91% -5,222.22% -381.66% -238.78%
EPS - - - - - - - - - - -0.0200 - -0.0200 -0.0100 - - - - -
Dividend per Share - - - - - - - - - - - - - - - - - - -
Announcement Date 06/08/20 18/08/21 18/11/21 16/03/22 11/05/22 16/08/22 16/08/22 15/11/22 22/03/23 24/05/23 30/08/23 30/08/23 20/11/23 26/03/24 - - - - -
1USD in Million
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025
Net Debt - - - - - - -
Net Cash position - - - - - - -
Leverage (Debt/EBITDA) - - - - - - -
Free Cash Flow - - - - - - -
ROE (net income / shareholders' equity) - - - - - - -
ROA (Net income/ Total Assets) - - - - - - -
Assets 1 - - - - - - -
Book Value Per Share - - - - - - -
Cash Flow per Share - - - - - - -
Capex - - - - - - -
Capex / Sales - - - - - - -
Announcement Date 12/03/20 23/02/21 16/03/22 22/03/23 26/03/24 - -
1USD in Million
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Ratings for BioLineRx Ltd.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
BIOLINERX LTD. Stock BioLineRx Ltd.
-56.81% 53.23M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+2.93% 108B
ARGENX SE Stock argenx SE
-2.24% 23.46B
BIONTECH SE Stock BioNTech SE
-14.60% 21.72B
GENMAB A/S Stock Genmab A/S
-7.05% 18.64B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-38.55% 17.45B
BEIGENE, LTD. Stock BeiGene, Ltd.
-8.83% 17.19B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+5.51% 13.99B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+37.49% 12.53B
VIKING THERAPEUTICS, INC. Stock Viking Therapeutics, Inc.
+329.39% 8.81B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. BLRX Stock
  4. Financials BioLineRx Ltd.